MANNKIND CORP Increase (Decrease) in Deferred Compensation
MANNKIND CORP (MNKD) reported Increase (Decrease) in Deferred Compensation of $35.90 million for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCompensation · last filed 2014-11-10
- 2014-06-30: Increase (Decrease) in Deferred Compensation 6 month $35.90M.
| Period end | Increase (Decrease) in Deferred Compensation 6 month |
|---|---|
| 2014-06-30 | $35.90M 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |